[ 69 ] showed no significant mortality benefit of remdesivir compared with placebo [ 28 , 44 ], although one study showed a trend towards reduced mortality in patients who received treatment earlier in their disease course (within 10 days of symptom onset) [ 44 ].
1
—
—